<DOC>
	<DOC>NCT00544310</DOC>
	<brief_summary>The objective is to evaluate the safety and initial efficacy of the Omrix Anti-Adhesion (AA) kit, Adhexil™ in preventing and/or reducing post-operative adhesions in patients undergoing surgery involving the ovaries.</brief_summary>
	<brief_title>Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil</brief_title>
	<detailed_description>Adhexil™ contains the components that form the anti-adhesive barrier, BAC and Thrombin. Thrombin is a sterile solution, containing highly purified human thrombin. BAC is a sterile, solution whose principal component is a concentrate of human fibrinogen. Adhexil™ is supplied in two vials and an application device.</detailed_description>
	<mesh_term>Ovarian Diseases</mesh_term>
	<criteria>Female patients aged 1845 years at screening Patients undergoing elective laparoscopic surgery due to known or suspected bilateral ovarian disease Pregnant (including ectopic pregnancy) or breastfeeding patient Patients with a documented diagnosis of cancer Patients with a lymphatic, hematologic or coagulation disorder Patients with a known or suspected hypersensitivity to blood, blood products or any constituent of Adhexil™ Patients who are immunocompromised, possess autoimmune disorders, or who are routinely taking anticoagulants. Patients who have participated in another clinical study within 30 days of enrolment. Investigator's opinion that the patient is medically unfit or would be at major risk if enrolled into the study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>